India’s CDMO Moment: Why Contract Manufacturing Is Becoming a Venture Category

Two Tailwinds, One Sector

India’s pharmaceutical contract development and manufacturing sector — CDMO, in the industry’s preferred shorthand — has spent the past several years riding two simultaneous tailwinds: a global “China plus one” reshoring push, as multinational pharma companies deliberately diversify manufacturing away from over-reliance on a single geography, and a genuine, decade-long build-out of India’s own biologics and complex-molecule manufacturing capability that has moved the country well beyond its historical reputation as purely a low-cost generics and API producer.

It is worth separating those two tailwinds explicitly, because they carry different risk profiles for an investor. The reshoring tailwind is, by nature, somewhat exposed to geopolitics and trade policy — it could, in principle, partially reverse if US-China relations shift, or if new tariff regimes make a different geography relatively more attractive. The capability-build tailwind is structural and considerably harder to reverse: once India’s manufacturing base has genuinely acquired the technical competence to produce complex biologics, antibody-drug conjugates, and peptide therapeutics to global quality standards, that competence does not simply disappear if a specific trade policy changes. The more durable investment thesis leans on the second tailwind, treating the first as a welcome accelerant rather than the foundation.

Sizing the Market Honestly

Estimates of the market’s current size vary meaningfully depending on methodology and scope — figures ranging from roughly $9 billion to $30 billion appear across different 2026 industry reports, with growth projections clustering around a 13 to 14 percent compound annual rate through the early 2030s regardless of which base figure one starts from. That range is worth acknowledging honestly rather than picking whichever number best supports a given narrative; the variance largely reflects differing definitions of what counts as “CDMO” activity — some estimates include the full breadth of API and generic finished-dose manufacturing, while others count only the higher-value complex-molecule and biologics segment specifically.

Whichever definition an investor prefers, the growth rate consensus across nearly every published estimate — low-to-mid double digits annually through the early 2030s — is the more reliable signal than any single absolute market-size figure, and it is a growth rate that comfortably outpaces the broader pharmaceutical industry’s own growth, evidence that India is genuinely gaining share of global outsourced manufacturing rather than merely growing in line with overall industry demand.

The “Reset Year”, Properly Understood

The De Facto Biobeat 2026 Report, released ahead of the industry’s major CPHI Frankfurt gathering, describes 2026 specifically as a “reset year” for Indian CDMOs — not a downturn, but a period in which multinational clients are slowing project decision-making and stretching out contract-signing timelines even as the underlying demand for outsourced manufacturing remains structurally intact.

That kind of language tends to alarm investors trained to read “reset” as a euphemism for trouble. In this case it is closer to the opposite: a genuine maturation point, where the sector shifts from riding pure cost-arbitrage and reshoring tailwinds toward competing on differentiated technical capability, and where the investable opportunity moves correspondingly from volume-driven capacity plays toward capability-driven specialization. A slower, more deliberate multinational client evaluation process is, in a real sense, evidence that Indian CDMOs are now being evaluated on the same rigorous, capability-focused criteria as their Western and Korean competitors, rather than winning contracts primarily on price — a shift that favors the CDMOs with genuine technical depth over those competing purely on cost.

Where the Capital Is Actually Going

That shift is visible in where the actual capital is going. Hyderabad-based Sai Life Sciences is targeting a tripling of manufacturing capacity over five years, building explicitly toward an end-to-end platform spanning drug discovery through commercial-scale manufacturing — a genuinely differentiated position, since most Indian CDMOs have historically specialized narrowly in either early discovery services or late-stage commercial manufacturing rather than offering both under one roof, a fragmentation that has historically forced a multinational sponsor to manage multiple separate vendor relationships across a single drug’s development lifecycle.

OneSource Specialty Pharma has committed more than $75 million specifically toward drug-device combination products and sterile fill-finish infrastructure, explicitly built to support the next wave of global GLP-1 therapy launches — a direct, concrete example of the manufacturing-capacity theme discussed elsewhere in this issue’s coverage of retatrutide and oral GLP-1 therapies, and a useful illustration of how quickly Indian CDMO capital expenditure decisions are now tracking global therapeutic-category demand shifts in near real time, rather than lagging them by the several years that used to be typical.

Akums Drugs and Pharmaceuticals has commissioned a new WHO-GMP-compliant injectables plant specifically to serve ampoule, vial, and pre-filled parenteral demand for regulated global markets, alongside roughly ₹250 to 300 crore in annual maintenance and growth capital expenditure — a genuinely substantial, sustained reinvestment rate for a company operating in what is still, by global standards, a relatively capital-constrained domestic financing environment relative to Western or even Chinese biomanufacturing peers.

The Quiet Regulatory Story

Regulatory alignment has been the quieter but arguably more consequential structural shift underlying all of this capacity expansion. CDSCO’s Schedule M upgrades have brought Indian manufacturing quality standards into closer alignment with US FDA and EMA expectations, removing what was historically one of the more persistent procurement hurdles multinational sponsors cited when evaluating Indian manufacturing partners — a hurdle that was, for years, a genuine and legitimate quality-assurance concern rather than mere protectionist friction, and one that Indian regulators have addressed methodically rather than superficially.

That alignment shows up directly in contract complexity and duration: biologics-manufacturing contract values are lengthening, and repeat-order rates from multinational sponsors are climbing, both signals of genuine trust built over multiple successful engagement cycles rather than one-off, price-driven contract awards. A multinational sponsor does not commit to a multi-year, higher-value biologics manufacturing contract with a partner it does not trust to execute reliably at that complexity level; the lengthening contract durations are, in effect, a revealed-preference signal of exactly the trust-building the Schedule M reforms were designed to produce.

What the Therapeutic Mix Reveals

The therapeutic-area mix within India’s CDMO sector tells its own story about where the country’s manufacturing capability has actually matured. Oncology products led 2024 CDMO revenue with roughly a 30 percent share — a category that requires the specialized containment and handling infrastructure needed for high-potency active pharmaceutical ingredients, and one Indian manufacturers have invested heavily in precisely because it commands premium pricing relative to standard generic manufacturing, since high-potency compound handling requires dedicated facility design, specialized ventilation and containment systems, and a level of operator safety protocol that a standard generics line simply does not need.

Antibody-drug conjugates, PROTACs, RNAi therapeutics, and multi-specific antibodies — each discussed as active areas of clinical development elsewhere in this issue — are the specific technical capabilities industry consultants now cite as the differentiators separating the CDMOs that will command premium, long-term contracts from those competing purely on cost in an increasingly commoditized generics and simple-API segment. An investor evaluating an Indian CDMO in 2026 should, in our own view, weight a company’s demonstrated capability across exactly this specific list of complex modalities considerably more heavily than its current revenue mix, which still, for most Indian CDMOs, skews toward the lower-margin generic and simple-API business that built the industry in the first place.

Consolidation Is Following Capability

Consolidation is following capability rather than the reverse, which is itself a useful signal for where value is actually accruing in the sector. Novo Holdings’ $16.5 billion acquisition of Catalent, while a global rather than India-specific transaction, sent a clear signal across the entire CDMO industry that end-to-end providers combining development, scale-up, and commercial manufacturing under one roof command a structural premium over single-stage manufacturing specialists — a dynamic Indian CDMOs pursuing the same integrated-platform strategy, Sai Life Sciences among them, are explicitly positioning to capture, and one that should inform how a venture investor thinks about exit multiples for the Indian CDMO companies in this space over the coming several years.

Where We Are Looking

For a venture fund, the investable opportunity in India’s CDMO reset is less about backing another generic small-molecule API manufacturer competing purely on cost — that segment is large, real, but structurally low-margin and increasingly commoditized — and more about identifying the specific companies building genuine technical differentiation in peptides, biologics, and high-potency compound handling, categories where India is still meaningfully building capability relative to established Western and increasingly South Korean and Chinese competitors, and where a five-to-ten-year investment horizon can capture real capability-building rather than merely riding a cyclical reshoring wave that could, in principle, reverse as easily as it began.

The Moment to Look Closer, Not Away

A “reset year” in a sector’s own trade press is usually the moment worth paying closest attention to, not the moment to wait out from the sidelines — it is precisely when capital discipline separates the companies building durable technical capability from the ones that were simply riding a favorable cost-arbitrage cycle, and durable technical capability is the harder, more valuable thing to identify while it is still underpriced, before the broader market has fully repriced the sector’s genuine winners.